CytoDyn Announces Company Updates and Investment Community Update Webcast
July 11, 2023 16:05 ET
|
CytoDyn Inc.
Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July 24th, 2023, at 1 PM PT / 4 PM ET ...
CytoDyn Announces President Takes Medical Leave of Absence
May 24, 2023 17:05 ET
|
CytoDyn Inc.
Antonio Migliarese assumes interim President roleDr. Melissa Palmer appointed interim Chief Medical OfficerDr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor VANCOUVER, Washington,...
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023 08:30 ET
|
CytoDyn Inc.
VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022 08:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022 08:30 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
October 28, 2022 17:15 ET
|
CytoDyn Inc.
Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other HIV-related, NASH, and oncology indications Webcast to be held Monday, October 31, 2022, at 5:30...
CytoDyn Announces Appointment of Additional Directors with Industry Experience
October 20, 2022 08:30 ET
|
CytoDyn Inc.
Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board VANCOUVER, Wash., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY)...
CytoDyn to Hold Webcast to Provide a Quarterly Company Update
September 19, 2022 08:30 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President
July 13, 2022 08:30 ET
|
CytoDyn Inc.
VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab
July 11, 2022 08:30 ET
|
CytoDyn Inc.
$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV VANCOUVER, Washington, July 11, 2022 (GLOBE...